Literature DB >> 2597113

Inhibition of apolipoprotein B net synthesis and secretion from cultured rat hepatocytes by the calcium-channel blocker diltiazem.

T C Kwong1, J D Sparks, D J Pryce, J F Cianci, C E Sparks.   

Abstract

1. The effect of the Ca2+-channel blocker diltiazem on hepatic apolipoprotein B (apo B) synthesis and secretion was studied in 12-18 h cultures of collagenase-dispersed rat hepatocytes. 2. The presence of diltiazem in the medium decreased apo B secretion by hepatocytes in a concentration-dependent manner. At 25 microM, diltiazem inhibited apo B secretion by approx. 36%, but there was no evidence of intracellular accumulation of apo B. 3. The inhibition of apo B secretion by hepatocytes was significantly correlated with cell-associated diltiazem (r = 0.72, P less than 0.01). 4. The rate of apo B secretion remained linear over 16 h even in the presence of 50 microM-diltiazem. 5. At diltiazem concentrations in the medium which were inhibitory for apo B secretion, [14C]acetate incorporation into cellular lipids and [35S]methionine incorporation into protein were enhanced. 6. Diltiazem inhibited the secretion of the apo B variants with a preferential inhibition of the higher-molecular-mass form of apo B (apo BH) over the lower-molecular-mass form (apo BL) at diltiazem concentrations in the medium greater than 25 microM. 7. Together, these results suggest that Ca2+ may play an important role in the synthesis and secretion of apo B-containing lipoproteins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2597113      PMCID: PMC1133444          DOI: 10.1042/bj2630411

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  17 in total

1.  On the protein defect in abetalipoproteinemia.

Authors:  A M Gotto; R I Levy; K John; D S Fredrickson
Journal:  N Engl J Med       Date:  1971-04-15       Impact factor: 91.245

2.  Inhibition by chloroquine of the secretion of very low density lipoproteins by cultured rat hepatocytes.

Authors:  J O Nossen; A C Rustan; T Barnard; C A Drevon
Journal:  Biochim Biophys Acta       Date:  1984-02-17

3.  Pharmacokinetic model of diltiazem.

Authors:  E U Kölle; H R Ochs; K O Vollmer
Journal:  Arzneimittelforschung       Date:  1983

4.  Hepatic and intestinal contribution of two forms of apolipoprotein B to plasma lipoprotein fractions in the rat.

Authors:  C E Sparks; O Hnatiuk; J B Marsh
Journal:  Can J Biochem       Date:  1981-08

5.  Relationship between plasma glucose and insulin concentration, glucose production, and glucose disposal in normal subjects and patients with non-insulin-dependent diabetes.

Authors:  Y D Chen; C Y Jeng; C B Hollenbeck; M S Wu; G M Reaven
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

6.  Metabolism of two forms of apolipoprotein B of VLDL by rat liver.

Authors:  C E Sparks; D J Rader; J B Marsh
Journal:  J Lipid Res       Date:  1983-02       Impact factor: 5.922

7.  Role of insulin in lipoprotein secretion by cultured rat hepatocytes.

Authors:  W Patsch; S Franz; G Schonfeld
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

8.  Variant forms of plasma apolipoprotein B. Hepatic and intestinal biosynthesis and heterogeneous metabolism in the rat.

Authors:  A L Wu; H G Windmueller
Journal:  J Biol Chem       Date:  1981-04-25       Impact factor: 5.157

9.  Apolipoprotein B is structurally and metabolically heterogeneous in the rat.

Authors:  J Elovson; Y O Huang; N Baker; R Kannan
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

10.  Apolipoprotein B variant derived from rat intestine.

Authors:  K V Krishnaiah; L F Walker; J Borensztajn; G Schonfeld; G S Getz
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

View more
  1 in total

1.  Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production.

Authors:  Meihui Pan; Arthur I Cederbaum; Yuan-Li Zhang; Henry N Ginsberg; Kevin Jon Williams; Edward A Fisher
Journal:  J Clin Invest       Date:  2004-05       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.